The expression of circ-PAN3 was also found to be up-regulated in patients with AML with both refractory and recurrent conditions; the down-regulation of circ-PAN3 restored the sensitivity of THP-1 cells to Adriamycin [37]. Here, PAN3 is linked to acute myeloid leukemia.